Sharma Anjali, Hoover Donald R, Shi Qiuhu, Gustafson Deborah, Plankey Michael W, Hershow Ronald C, Tien Phyllis C, Golub Elizabeth T, Anastos Kathryn
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Department of Statistics and Biostatistics, Rutgers University, Piscataway, New Jersey, United States of America.
PLoS One. 2015 Dec 23;10(12):e0143740. doi: 10.1371/journal.pone.0143740. eCollection 2015.
Early HIV studies suggested protective associations of overweight against mortality, yet data are lacking for the era of potent highly active antiretroviral therapy (HAART). We evaluated associations of pre-HAART initiation body mass index (BMI) with mortality among HAART-using women.
Prospective study of time to death after HAART initiation among continuous HAART users in the Women's Interagency HIV Study. Unadjusted Kaplan-Meier and adjusted proportional hazards survival models assessed time to AIDS and non-AIDS death by last measured pre-HAART BMI.
Of 1428 continuous HAART users 39 (2.7%) were underweight, 521 (36.5%) normal weight, 441 (30.9%) overweight, and 427 (29.9%) obese at time of HAART initiation. A total of 322 deaths occurred during median follow-up of 10.4 years (IQR 5.9-14.6). Censoring at non-AIDS death, the highest rate of AIDS death was observed among underweight women (p = 0.0003 for all 4 categories). In multivariate models, women underweight prior to HAART died from AIDS more than twice as rapidly vs. normal weight women (aHR 2.04, 95% CI 1.03, 4.04); but being overweight or obese (vs. normal weight) was not independently associated with AIDS death. Cumulative incidence of non-AIDS death was similar across all pre-HAART BMI categories.
Among continuous HAART-using women, being overweight prior to initiation was not associated with lower risk of AIDS or non-AIDS death. Being underweight prior to HAART was associated with over double the rate of AIDS death in adjusted analyses. Although overweight and obesity may be associated with many adverse health conditions, neither was predictive of mortality among the HAART-using women.
早期的艾滋病病毒研究表明超重对死亡率有保护作用,但在高效抗逆转录病毒疗法(HAART)时代的数据却很缺乏。我们评估了开始接受HAART治疗前的体重指数(BMI)与使用HAART治疗的女性死亡率之间的关联。
在女性机构间艾滋病研究中,对持续使用HAART治疗的患者开始治疗后至死亡时间进行前瞻性研究。未调整的Kaplan-Meier法和调整后的比例风险生存模型通过最后一次测量的HAART治疗前BMI评估艾滋病和非艾滋病死亡时间。
在1428名持续使用HAART治疗的患者中,39人(2.7%)在开始HAART治疗时体重过轻,521人(36.5%)体重正常,441人(30.9%)超重,427人(29.9%)肥胖。在中位随访10.4年(四分位间距5.9 - 14.6年)期间,共发生322例死亡。以非艾滋病死亡为截尾事件,体重过轻的女性中艾滋病死亡率最高(所有4组比较,p = 0.0003)。在多变量模型中,HAART治疗前体重过轻的女性死于艾滋病的速度是体重正常女性的两倍多(校正风险比2.04,95%置信区间1.03,4.04);但超重或肥胖(与体重正常相比)与艾滋病死亡无独立关联。所有HAART治疗前BMI类别中非艾滋病死亡的累积发生率相似。
在持续使用HAART治疗的女性中,开始治疗前超重与艾滋病或非艾滋病死亡风险降低无关。HAART治疗前体重过轻与校正分析中艾滋病死亡率增加一倍以上有关。尽管超重和肥胖可能与许多不良健康状况相关,但两者均不能预测使用HAART治疗的女性的死亡率。